NEW YORK (GenomeWeb News) – Cellectis today announced a licensing agreement with the University of Minnesota giving it exclusive rights to use inventions related to TAL effector-mediated DNA recognition and cleavage.
Financial and other terms of the deal were not disclosed.
The technology was co-developed at the University of Minnesota and Iowa State University, and in a statement, Cellectis said that it shows promising results in genome engineering. It is complementary to Cellectis' proprietary meganuclease technology, the Paris-based genome engineering firm added.